Veru Q2 net loss narrows as expenses decline

Veru

13/05/2026 11:39

Overview

US biopharma firm's fiscal Q2 net loss narrowed year-over-year

Research and development and administrative expenses both declined from prior year

Outlook

Company plans to prioritize internal cash for enobosarm development; advancement of sabizabulin depends on new funding

Result Drivers

EXPENSE REDUCTIONS - Lower research and development and administrative expenses narrowed net loss in Q2

Company press release: ID:nGNX6BHKLg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.12
Q2 Net Income
-$2.70 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Veru Inc is $25.00, about 1,001.3% above its May 12 closing price of $2.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)